Gary Schiller, MD, on the STOMP Study in Myeloma

Gary Schiller, MD, of the University of California, Los Angeles, discusses the STOMP study and the safety profile of the triplet selinexor, carfilzomib, and dexamethasone in myeloma. Dr. Schiller and colleagues presented the study’s results during the 2022 American Society of Hematology Annual Meeting.